These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30373998)

  • 41. Use and safety of denosumab in cancer patients.
    Manzaneque A; Chaguaceda C; Mensa M; Bastida C; Creus-Baró N
    Int J Clin Pharm; 2017 Jun; 39(3):522-526. PubMed ID: 28382583
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases.
    Nishimukai A; Higuchi T; Ozawa H; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Miyoshi Y
    Breast Cancer; 2017 Mar; 24(2):245-253. PubMed ID: 27040403
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures.
    Pittman K; Antill YC; Goldrick A; Goh J; de Boer RH
    Asia Pac J Clin Oncol; 2017 Aug; 13(4):266-276. PubMed ID: 27862983
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Basic and clinical associations between bone and cancer.
    He F; Matsumoto Y
    Immunol Med; 2020 Sep; 43(3):103-106. PubMed ID: 32301686
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of denosumab versus zoledronic acid in patients with bone metastases: a systematic review and meta-analysis.
    Sun L; Yu S
    Am J Clin Oncol; 2013 Aug; 36(4):399-403. PubMed ID: 22772430
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial.
    Barrett-Lee P; Casbard A; Abraham J; Hood K; Coleman R; Simmonds P; Timmins H; Wheatley D; Grieve R; Griffiths G; Murray N
    Lancet Oncol; 2014 Jan; 15(1):114-22. PubMed ID: 24332514
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Successful conservative treatment of jaw osteonecrosis caused by denosumab in patients with multiple bone metastasis.
    Ohga N; Sato J; Asaka T; Morimoto M; Yamazaki Y; Kitagawa Y
    J Oral Sci; 2018; 60(1):159-162. PubMed ID: 29576576
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bone targeted therapies in advanced breast cancer.
    Biskup E; Cai F; Vetter M
    Swiss Med Wkly; 2017 Jul; 147():w14440. PubMed ID: 28695563
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries.
    Body JJ; Gatta F; De Cock E; Tao S; Kritikou P; Wimberger P; Mebis J; Peeters M; Pedrazzoli P; Caraceni A; Adamo V; Hechmati G
    Support Care Cancer; 2017 Sep; 25(9):2823-2832. PubMed ID: 28429148
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study.
    Kajizono M; Sada H; Sugiura Y; Soga Y; Kitamura Y; Matsuoka J; Sendo T
    Biol Pharm Bull; 2015; 38(12):1850-5. PubMed ID: 26632176
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment dynamics of bone-targeting agents among men with bone metastases from prostate cancer in the United States.
    Butler AM; Cetin K; Hernandez RK; Diane Reams B; Overman RA; I Kim J; Hirsch BR; Abernethy AP; Liede A; Alan Brookhart M
    Pharmacoepidemiol Drug Saf; 2018 Feb; 27(2):229-238. PubMed ID: 29316026
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
    Xie J; Namjoshi M; Wu EQ; Parikh K; Diener M; Yu AP; Guo A; Culver KW
    J Manag Care Pharm; 2011 Oct; 17(8):621-43. PubMed ID: 21942303
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Denosumab, an Alternative to Bisphosphonates but also Associated with Osteonecrosis of the Jaw--What is the Risk?
    Sidhu HK
    Dent Update; 2015 Jun; 42(5):436-8, 440. PubMed ID: 26964445
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association of Behavioral Nudges With High-Value Evidence-Based Prescribing in Oncology.
    Takvorian SU; Ladage VP; Wileyto EP; Mace DS; Beidas RS; Shulman LN; Bekelman JE
    JAMA Oncol; 2020 Jul; 6(7):1104-1106. PubMed ID: 32352478
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates.
    Ristow O; Gerngroß C; Schwaiger M; Hohlweg-Majert B; Kehl V; Jansen H; Hahnefeld L; Koerdt S; Otto S; Pautke C
    Br J Oral Maxillofac Surg; 2014 Apr; 52(4):308-13. PubMed ID: 24582013
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Denosumab for the treatment of bone disease in solid tumors and multiple myeloma.
    Yee AJ; Raje NS
    Future Oncol; 2018 Feb; 14(3):195-203. PubMed ID: 29052442
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impending Atypical Femoral Fracture in a Patient of Breast Cancer With Bone Metastases Receiving Long-term Denosumab.
    Sugihara T; Koizumi M; Hayakawa K; Ito Y; Sata N
    Clin Nucl Med; 2018 May; 43(5):365-366. PubMed ID: 29517548
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Incidence of hypocalcemia in patients receiving denosumab for prevention of skeletal-related events in bone metastasis.
    Yerram P; Kansagra S; Abdelghany O
    J Oncol Pharm Pract; 2017 Apr; 23(3):179-184. PubMed ID: 26830549
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety of Denosumab Versus Zoledronic Acid in Patients with Bone Metastases: A Meta-Analysis of Randomized Controlled Trials.
    Chen F; Pu F
    Oncol Res Treat; 2016; 39(7-8):453-9. PubMed ID: 27487236
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Osteoclast inhibitors to prevent bone metastases in men with high-risk, non-metastatic prostate cancer: A systematic review and meta-analysis.
    Hayes AR; Brungs D; Pavlakis N
    PLoS One; 2018; 13(1):e0191455. PubMed ID: 29370211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.